ClinicalTrials.gg
CompletedNCT00976716Updated Feb 2, 2021Results posted

An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain

A Phase 3 interventional study of Celecoxib in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 11 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing celecoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Celecoxib · Pain.

Enrollment
11th of 22
80 · median 79
Started
2009
with 1 other
Phase 3
3 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
4 of 22
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 22 studies testing celecoxib in Pain, this one is the 11th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 8th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 22 studies testing celecoxib in Pain is open now. The open studies under Pain, anywhere →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing celecoxib in Pain as a file.
02

Study summary

To investigate efficacy, safety and tolerability of Celecoxib in patients with posttraumatic pain for the duration of 8 days.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • posttraumatic pain
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with posttraumatic pain which is able to be controlled with an oral NSAID
  • Patients with "pain" that meets both of the following criteria within 48 hours after injury:

"Pain" Pain intensity (Categorical): "Moderate pain" or "Severe pain" Pain intensity (VAS): 45.0 mm or more

  • Patients with "inflammation" that meets the following criteria within 48 hours after injury.

"Inflammation" Categorical: "Mild", "Moderate" or "Severe"

Exclusion criteria

Exclusion Criteria:

  • Patients who have received analgesics and anaesthetics for injury
  • Patients with a history/complication of aspirin-induced asthma
  • Patients taking excluded medications
  • Patients with a history/complication of ischaemic heart disease, serious cardiac arrhythmias, cardiac failure congestive and cerebrovascular disorder or with a history/plan of revascularization
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Celecoxib

    Drug: Celecoxib

Interventions

  • Day 1 * The first dose: Celecoxib 400mg * The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8) - Celecoxib 200mg twice daily

06

What researchers measure

Primary outcomes

  1. Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good")

    The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until Final Visit.

    Time frame: 8 days

Secondary outcomes

  1. Patient Impressions Within 8 Days Post-first Dose (the Number of Subjects Who Have Rated "Excellent" and "Good")

    The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until each time point.

    Time frame: 6 hours post first dose and before sleep on Day 1, before sleep on Day 2, Day 4 (Visit 2) and Day 8 (Visit 3)

  2. Pain Intensity (PI) of Pain at Rest (Spontaneous Pain) as Measured by Visual Analog Scale (VAS) Within 8 Days Post-first Dose

    The PI of pain at rest (spontaneous pain) was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.

    Time frame: Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)

  3. PI of Pain on Active Movement as Measured by VAS Within 8 Days Post-first Dose

    The PI of pain on active movement was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.

    Time frame: Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)

  4. Pain Intensity Differences (PID) in Pain at Rest (Spontaneous Pain) Within 8 Days Post-first Dose

    The PID score was obtained by subtracting the PI (by VAS: 0 mm=no pain, 100 mm=worst possible pain) at each time point from the Baseline PI score. Increase in PID scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

    Time frame: Two, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)

  5. PID in Pain on Active Movement Within 8 Days Post-first Dose

    The PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

    Time frame: 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)

  6. Sum of Pain Intensity Differences (SPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose

    The SPID was derived according to the following rule: each PID was weighted by the width of time interval between previous and current time points in hours and summed up to 6 hours post-first dose

    Time frame: 6 hours

  7. Peak Pain Intensity Difference (PPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose

    The PPID was obtained by subtracting the maximum value of pain intensity (PI) at a time point among 2 to 6 hours post first dose from baseline value of PI for each patient.

    Time frame: Two, 4 and 6 hours post first dose

  8. Severity of Inflammatory Symptoms (Swelling) Within 8 Days Post-first Dose

    The investigator assessed the swelling, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

    Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)

  9. Severity of Inflammatory Symptoms (Redness) Within 8 Days Post-first Dose

    The investigator assessed the redness, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

    Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)

  10. Severity of Inflammatory Symptoms (Localized Warmth) Within 8 Days Post First Dose

    The investigator assessed the localized warmth, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

    Time frame: Baseline, Days 4 (Visit 2) and 8 (Visit 3)

  11. Withdrawal Due to Lack of Efficacy

    The number of subjects who withdrew due to insufficient clinical response was evaluated.

    Time frame: 8 days

  12. Summary of Adverse Events

    The number of subjects who experienced adverse events (AEs; all-causality and treatment-related) based on safety assessment was summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.

    Time frame: 8 days

07

Results

Posted May 19, 2011

Participant flow

Subjects were screened at 12 centers in Japan.

Participant flow — Overall Study
MilestoneCelecoxib
Started80
Completed79
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPatient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good")

The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until Final Visit.

Time frame:
8 days
Reported as:
Number · Participants
Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good")
ParticipantsCelecoxib
Patient Impressions at Final Visit (the Number of Participants Who Have Rated "Excellent" and "Good")70
SecondaryPatient Impressions Within 8 Days Post-first Dose (the Number of Subjects Who Have Rated "Excellent" and "Good")

The patient impression of the study medication was entered in the patient diary based on the following categories: "excellent," "good," "fair" and "poor." Efficacy was based on the patient impression of the study medication ("excellent" and "good") from the first study medication until each time point.

Time frame:
6 hours post first dose and before sleep on Day 1, before sleep on Day 2, Day 4 (Visit 2) and Day 8 (Visit 3)
Reported as:
Number · Participants
Patient Impressions Within 8 Days Post-first Dose (the Number of Subjects Who Have Rated "Excellent" and "Good")
ParticipantsCelecoxib
Day 1, 6 hours post first dose (n=80)44
Day 1, before sleep (n=80)48
Day 2, before sleep (n=80)55
Visit 2 (Day 4), (n=80)60
Visit 3 (Day 8), (n=68)60
SecondaryPain Intensity (PI) of Pain at Rest (Spontaneous Pain) as Measured by Visual Analog Scale (VAS) Within 8 Days Post-first Dose

The PI of pain at rest (spontaneous pain) was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.

Time frame:
Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Reported as:
Mean · mm
Pain Intensity (PI) of Pain at Rest (Spontaneous Pain) as Measured by Visual Analog Scale (VAS) Within 8 Days Post-first Dose
mmCelecoxib
Baseline (n=80)59.9 ± 11.4
Day 1, 2 hours post first dose (n=80)47.3 ± 19.5
Day 1, 4 hours post first dose (n=80)42.5 ± 20.5
Day 1, 6 hours post first dose (n=80)40.3 ± 20.9
Day 1, before sleep (n=80)38.1 ± 20.0
Day 2, on awakening (n=80)34.8 ± 21.5
Day 2, before sleep (n=80)29.0 ± 22.0
Day 3, on awakening (n=80)24.8 ± 20.0
Day 3, before sleep (n=78)21.8 ± 19.1
Day 4, on awakening (n=78)18.4 ± 19.6
Day 4, before sleep (n=73)17.8 ± 18.9
Day 5, on awakening (n=73)15.3 ± 18.0
Day 5, before sleep (n=68)15.0 ± 18.7
Day 6, on awakening (n=68)12.4 ± 17.2
Day 6, before sleep (n=68)11.6 ± 17.3
Day 7, on awakening (n=68)11.3 ± 18.1
Day 7, before sleep (n=55)9.7 ± 16.2
Day 8, on awakening (n=55)8.6 ± 13.3
Visit 3 (Day 8) (n=73)7.2 ± 13.0
Final Visit (LOCF, n=80)7.3 ± 13.4
SecondaryPI of Pain on Active Movement as Measured by VAS Within 8 Days Post-first Dose

The PI of pain on active movement was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=worst possible pain.

Time frame:
Baseline, 2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Reported as:
Mean · mm
PI of Pain on Active Movement as Measured by VAS Within 8 Days Post-first Dose
mmCelecoxib
Baseline (n=79)75.5 ± 12.7
Day 1, 2 hours post first dose (n=77)61.4 ± 20.2
Day 1, 4 hours post first dose (n=77)55.3 ± 21.0
Day 1, 6 hours post first dose (n=77)51.5 ± 20.6
Day 1, before sleep (n=77)49.3 ± 21.0
Day 2, on awakening (n=77)45.5 ± 21.4
Day 2, before sleep (n=77)39.7 ± 22.6
Day 3, on awakening (n=77)35.5 ± 22.3
Day 3, before sleep (n=75)32.4 ± 21.8
Day 4, on awakening (n=75)27.2 ± 22.9
Day 4, before sleep (n=70)26.4 ± 21.0
Day 5, on awakening (n=70)23.5 ± 21.4
Day 5, before sleep (n=66)23.2 ± 22.0
Day 6, on awakening (n=66)19.2 ± 20.4
Day 6, before sleep (n=66)18.2 ± 20.1
Day 7, on awakening (n=66)17.1 ± 21.7
Day 7, before sleep (n=55)15.5 ± 20.7
Day 8, on awakening (n=55)14.3 ± 20.0
Visit 3 (Day8) (n=71)12.1 ± 18.7
Final Visit (LOCF, n=78)11.8 ± 18.7
SecondaryPain Intensity Differences (PID) in Pain at Rest (Spontaneous Pain) Within 8 Days Post-first Dose

The PID score was obtained by subtracting the PI (by VAS: 0 mm=no pain, 100 mm=worst possible pain) at each time point from the Baseline PI score. Increase in PID scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

Time frame:
Two, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Reported as:
Mean · mm
Pain Intensity Differences (PID) in Pain at Rest (Spontaneous Pain) Within 8 Days Post-first Dose
mmCelecoxib
Day 1, 2 hours post first dose (n=80)12.6 ± 14.8
Day 1, 4 hours post first dose (n=80)17.4 ± 16.0
Day 1, 6 hours post first dose (n=80)19.6 ± 16.3
Day 1, before sleep (n=80)21.8 ± 16.8
Day 2, on awakening (n=80)25.1 ± 19.1
Day 2, before sleep (n=80)30.9 ± 20.8
Day 3, on awakening (n=80)35.1 ± 18.7
Day 3, before sleep (n=78)37.9 ± 18.8
Day 4, on awakening (n=78)41.3 ± 19.7
Day 4, before sleep (n=73)41.8 ± 19.2
Day 5, on awakening (n=73)44.3 ± 18.4
Day 5, before sleep (n=68)45.4 ± 19.5
Day 6, on awakening (n=68)48.0 ± 17.7
Day 6, before sleep (n=68)48.8 ± 18.1
Day 7, on awakening (n=68)49.2 ± 19.0
Day 7, before sleep (n=55)50.2 ± 18.7
Day 8, on awakening (n=55)51.3 ± 17.3
Visit 3 (Day 8) (n=73)52.4 ± 15.5
Final Visit (LOCF, n=80)52.6 ± 15.2
SecondaryPID in Pain on Active Movement Within 8 Days Post-first Dose

The PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

Time frame:
2, 4 and 6 hours post first dose, and before sleep on Day 1, on awakening and before sleep on Days 2 to 7, on awakening on Day 8 and Visit 3 (Day 8)
Reported as:
Mean · mm
PID in Pain on Active Movement Within 8 Days Post-first Dose
mmCelecoxib
Day 1, 2 hours post first dose (n=77)14.3 ± 16.6
Day 1, 4 hours post first dose (n=77)20.4 ± 17.1
Day 1, 6 hours post first dose (n=77)24.3 ± 17.5
Day 1, before sleep (n=77)26.5 ± 17.5
Day 2, on awakening (n=77)30.3 ± 19.2
Day 2, before sleep (n=77)36.1 ± 22.0
Day 3, on awakening (n=77)40.2 ± 21.2
Day 3, before sleep (n=75)43.2 ± 21.5
Day 4, on awakening (n=75)48.5 ± 22.3
Day 4, before sleep (n=70)49.5 ± 20.6
Day 5, on awakening (n=70)52.5 ± 20.8
Day 5, before sleep (n=66)53.5 ± 21.6
Day 6, on awakening (n=66)57.5 ± 19.7
Day 6, before sleep (n=66)58.4 ± 19.9
Day 7, on awakening (n=66)59.6 ± 21.4
Day 7, before sleep (n=55)62.1 ± 20.6
Day 8, on awakening (n=55)63.3 ± 20.6
Visit 3 (Day 8) (n=71)63.6 ± 18.6
Final Visit (LOCF, n=78)63.7 ± 18.1
SecondarySum of Pain Intensity Differences (SPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose

The SPID was derived according to the following rule: each PID was weighted by the width of time interval between previous and current time points in hours and summed up to 6 hours post-first dose

Time frame:
6 hours
Reported as:
Mean · mm
Sum of Pain Intensity Differences (SPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose
mmCelecoxib
Pain at rest (n=80)99.3 (79.9 to 118.7)
Pain on active movement (n=77)118.2 (96.7 to 139.6)
SecondaryPeak Pain Intensity Difference (PPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose

The PPID was obtained by subtracting the maximum value of pain intensity (PI) at a time point among 2 to 6 hours post first dose from baseline value of PI for each patient.

Time frame:
Two, 4 and 6 hours post first dose
Reported as:
Mean · mm
Peak Pain Intensity Difference (PPID) for Pain at Rest (Spontaneous Pain) and on Active Movement Until 6 Hours Post-first Dose
mmCelecoxib
Pain at rest (n=80)22.2 (18.6 to 25.8)
Pain on active movement (n=77)26.7 (22.6 to 30.7)
SecondarySeverity of Inflammatory Symptoms (Swelling) Within 8 Days Post-first Dose

The investigator assessed the swelling, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

Time frame:
Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Reported as:
Number · Participants
Severity of Inflammatory Symptoms (Swelling) Within 8 Days Post-first Dose
ParticipantsCelecoxib
None at Baseline (n=80)0
None at Visit 2 (Day 4) (n=80)5
None at Visit 3 (Day 8) (n=68)38
None at Final Visit (n=80)41
Mild at Baseline (n=80)24
Mild at Visit 2 (Day 4) (n=80)69
Mild at Visit 3 (Day 8) (n=68)26
Mild at Final Visit (n=80)35
Moderate at Baseline (n=80)48
Moderate at Visit 2 (Day 4) (n=80)5
Moderate at Visit 3 (Day 8) (n=68)4
Moderate at Final Visit (n=80)4
Severe at Baseline (n=80)8
Severe at Visit 2 (Day 4) (n=80)1
Severe at Visit 3 (Day 8) (n=68)0
Severe at Final Visit (n=80)0
SecondarySeverity of Inflammatory Symptoms (Redness) Within 8 Days Post-first Dose

The investigator assessed the redness, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

Time frame:
Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Reported as:
Number · Participants
Severity of Inflammatory Symptoms (Redness) Within 8 Days Post-first Dose
ParticipantsCelecoxib
None at Baseline (n=80)16
None at Visit 2 (Day 4) (n=80)51
None at Visit 3 (Day 8) (n=68)64
None at Final Visit (n=80)73
Mild at Baseline (n=80)40
Mild at Visit 2 (Day 4) (n=80)28
Mild at Visit 3 (Day 8) (n=68)4
Mild at Final Visit (n=80)7
Moderate at Baseline (n=80)19
Moderate at Visit 2 (Day 4) (n=80)1
Moderate at Visit 3 (Day 8) (n=68)0
Moderate at Final Visit (n=80)0
Severe at Baseline (n=80)5
Severe at Visit 2 (Day 4) (n=80)0
Severe at Visit 3 (Day 8) (n=68)0
Severe at Final Visit (n=80)0
SecondarySeverity of Inflammatory Symptoms (Localized Warmth) Within 8 Days Post First Dose

The investigator assessed the localized warmth, using the categories "None," "Mild," "Moderate," and "Severe" at Baseline, Visit 2 (Day 4), Visit 3 (Day 8) and Final Visit.

Time frame:
Baseline, Days 4 (Visit 2) and 8 (Visit 3)
Reported as:
Number · Participants
Severity of Inflammatory Symptoms (Localized Warmth) Within 8 Days Post First Dose
ParticipantsCelecoxib
None at Baseine (n=80)8
None at Visit 2 (Day 4) (n=80)63
None at Visit 3 (Day 8) (n=68)66
None at Final Visit (n=80)76
Mild at Baseine (n=80)43
Mild at Visit 2 (Day 4) (n=80)17
Mild at Visit 3 (Day 8) (n=68)2
Mild at Final Visit (n=80)4
Moderate at Baseine (n=80)23
Moderate at Visit 2 (Day 4) (n=80)0
Moderate at Visit 3 (Day 8) (n=68)0
Moderate at Final Visit (n=80)0
Severe at Baseine (n=80)6
Severe at Visit 2 (Day 4) (n=80)0
Severe at Visit 3 (Day 8) (n=68)0
Severe at Final Visit (n=80)0
SecondaryWithdrawal Due to Lack of Efficacy

The number of subjects who withdrew due to insufficient clinical response was evaluated.

Time frame:
8 days
Reported as:
Number · Participants
Withdrawal Due to Lack of Efficacy
ParticipantsCelecoxib
Withdrawal Due to Lack of Efficacy0
SecondarySummary of Adverse Events

The number of subjects who experienced adverse events (AEs; all-causality and treatment-related) based on safety assessment was summarized. The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.

Time frame:
8 days
Reported as:
Number · Participants
Summary of Adverse Events
ParticipantsCelecoxib
AEs: all-causality10
AEs: treatment-related8
Severe AEs: all-causality0
Severe AEs: treatment-realted0
Serious AEs: all-causality0
Serious AEs: treatment-related0
Discontinuation due to all-causality AEs1
Discontinuation due to treatment-related AEs1
DR/TD due to all-causality AEs0
DR/TD due to treatment-related AEs0

Adverse events

Collected over 8 days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—0/80 (0%)10/80 (12.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCelecoxib
Beta 2 microglobulin urine increasedInvestigations5/80
Beta-N-acetyl-D-glucosaminidase increasedInvestigations3/80
Blood creatine phosphokinase increasedInvestigations3/80
Blood lactate dehydrogenase increasedInvestigations2/80
DiarrhoeaGastrointestinal disorders1/80
Muscle strainInjury, poisoning and procedural complications1/80
Alanine aminotransferase increasedInvestigations1/80
Aspartate aminotransferase increasedInvestigations1/80
Blood bilirubin increasedInvestigations1/80
Urobilin urine presentInvestigations1/80

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Celecoxib
Mean37.1 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Celecoxib
Female39
Male41
08

Study locations

11 sites
  • Pfizer Investigational Site
    Funabashi, Chiba, Japan
  • Pfizer Investigational Site
    Ichikawa, Chiba, Japan
  • Pfizer Investigational Site
    Matsudo, Chiba, Japan
  • Pfizer Investigational Site
    Sagamihara, Kanagawa, Japan
  • Pfizer Investigational Site
    Ageo, Saitama, Japan
  • Pfizer Investigational Site
    Saitama-shi, Saitama, Japan
  • Pfizer Investigational Site
    Edogawaku, Tokyo, Japan
  • Pfizer Investigational Site
    Kotoku, Tokyo, Japan
  • Pfizer Investigational Site
    Nerimaku, Tokyo, Japan
  • Pfizer Investigational Site
    Toshimaku, Tokyo, Japan
  • Pfizer Investigational Site
    Kofu, Yamanashi, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2009
First posted
Sep 14, 2009
Start
Sep 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
May 19, 2011
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00976716
Responsible party
Sponsor
First posted
Sep 14, 2009
Start date
Sep 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
May 19, 2011
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion